• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-IDH1 antibody :: Mouse IDH1 (Isocitrate Dehydrogenase) Monoclonal Antibody

Scan QR to view Datasheet
Catalog # MBS439694
Unit / Price
Scan QR to view Datasheet
  0.02 mg (With BSA & Azide at 0.2mg/ml)  /  $190 +1 FREE 8GB USB
  0.1 mg (With BSA & Azide at 0.2mg/ml)  /  $300 +1 FREE 8GB USB
  0.1 mg (Without BSA & Azide at 1mg/ml)  /  $310 +1 FREE 8GB USB
Product Name

IDH1 (Isocitrate Dehydrogenase), Monoclonal Antibody

Popular Item
Full Product Name

IDH1 (Isocitrate Dehydrogenase) Mouse Monoclonal Antibody

Product Synonym Names
Cytosolic NADP-isocitrate dehydrogenase; Epididymis luminal protein 216; Epididymis secretory protein Li 26; HEL-216; HEL-S-26; ICDH; IDCD; IDH1; IDP; IDPC; Isocitrate dehydrogenase [NADP] cytoplasmic; Isocitrate dehydrogenase 1 (NADP+) soluble; NADP dependent isocitrate dehydrogenase peroxisomal; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase; PICD
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O75874
IgG1, kappa
Clone Number
Species Reactivity
Others not known
It recognizes a 45kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming alpha-ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of alpha-ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
7.0ml of Ready-to-Use for IHC staining of formalin-fixed tissues.
Cellular Localization
Cytoplasmic & Nuclear
Recombinant fragment (119 Amino acid residues around aa 280-420) of human IDH1 protein
Hu-Chromosome Location
Positive Control
HepG2, HeLa, HT29 or MCF7 cells. Breast, Colon or Prostate Carcinoma.
Preparation and Storage
Store at 2 to 8 degree C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
Other Notes
Small volumes of anti-IDH1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-IDH1 antibody
Flow Cytometry (FC/FACS), Immunofluorescence (IF), Western Blot (WB), Immunohistochemistry (IHC) Formalin
Application Notes for anti-IDH1 antibody
Flow Cytometry (0.5-1ug/million cells in 0.1ml)
Immunofluorescence (0.5-1ug/ml)
Western Blot (0.5-1ug/ml)
Immunohistochemistry (Formalin-fixed) (Incubate for 30 minutes at RT)
(Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes)
Optimal dilution for a specific application should be determined.

Immunohistochemistry (IHC) of anti-IDH1 antibody
Formalin-fixed, paraffin-embedded human Colon Carcinoma stained with IDH1 Monoclonal Antibody (IDH1/1152).
anti-IDH1 antibody Immunohistochemistry (IHC) (IHC) image
Immunohistochemistry (IHC) of anti-IDH1 antibody
Formalin-fixed, paraffin-embedded human Prostate Carcinoma stained with IDH1 Monoclonal Antibody (IDH1/1152).
anti-IDH1 antibody Immunohistochemistry (IHC) (IHC) image
NCBI/Uniprot data below describe general gene information for IDH1. It may not necessarily be applicable to this product.
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
NCBI Official Full Name
isocitrate dehydrogenase
NCBI Official Synonym Full Names
isocitrate dehydrogenase (NADP(+)) 1, cytosolic
NCBI Official Symbol
NCBI Official Synonym Symbols
  [Similar Products]
NCBI Protein Information
isocitrate dehydrogenase [NADP] cytoplasmic
UniProt Protein Name
Isocitrate dehydrogenase [NADP] cytoplasmic
UniProt Synonym Protein Names
Cytosolic NADP-isocitrate dehydrogenase; IDP; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase
Protein Family
UniProt Gene Name
UniProt Synonym Gene Names
PICD; IDH  [Similar Products]
UniProt Entry Name
NCBI Summary for IDH1
Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production. Alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Sep 2013]
UniProt Comments for IDH1
IDH1: an oxidoreductase that catalyzes the third step of the TCA cycle: the oxidative decarboxylation of isocitrate, consuming NADP(+), and producing alpha-ketoglutarate (alpha-KG) and CO2. Alpha-KG is an activator the dioxygenases that hydroxylate the transcription factor HIF and lead to its degradation by VHL. Since HIF turns on oncogenic pathways, IDH1 has apparent tumor suppressor activity. Homo-dimerization is required for activity. Each subunit binds 1 magnesium or manganese ion. IDH1 is located in the cytosol and peroxisomes. Somatic mutations affecting arginine 132 (R132) are found in 80% of grade II?III gliomas and secondary glioblastomas in humans, and cause disease in a tissue-specific fashion. Only a single copy of the gene has been found to be mutated in tumours. Mutations of R132 to H, C, S, G, V, or L have been reported to be neomorphic, abolishing the conversion of isocitrate to alpha-KG. Instead, alpha-KG is converted to R(-)-2-hydroxyglutarate (2HG). Elevated levels of 2HG correlate with an elevated risk of malignant brain tumors. Neomorphic mutations in IDH1 and IDH2 convert alpha-KG to 2-hydroxyglutarate (2-HG) occur in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML).

Protein type: EC; Carbohydrate Metabolism - citrate (TCA) cycle; Other Amino Acids Metabolism - glutathione; Oxidoreductase

Chromosomal Location of Human Ortholog: 2q33.3

Cellular Component: cytoplasm; cytosol; peroxisomal matrix; peroxisome

Molecular Function: (R)-2-hydroxyglutarate dehydrogenase activity; isocitrate dehydrogenase (NADP+) activity; magnesium ion binding; protein homodimerization activity; receptor binding

Biological Process: 2-oxoglutarate metabolic process; isocitrate metabolic process; NADPH regeneration

Disease: Glioma Susceptibility 1
Product References and Citations for anti-IDH1 antibody
Geisbrecht, B.V. and Gould, S.J. 1999. The human PICD gene encodes a cytoplasmic and peroxisomal NADP+-dependent isocitrate dehydrogenase. J. Biol. Chem. 274: 30527-30533

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

Contact Us

Please fill out the form below and our representative will get back to you shortly.